• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Industry Voices: Biosimilars and Trade Secrets

Article

Trade secrets may potentially be used to protect manufacturing processes for biological drugs--yet there is concern that the new law on biosimilars, the BPCIA (Biologics Price Competition and Innovation Act of 2009), and the accompanying FDA regulations, may expose trade secrets of both originators and biosimilar applicants.

Trade secrets may potentially be used to protect manufacturing processes for biological drugs--yet there is concern that the new law on biosimilars, the BPCIA (Biologics Price Competition and Innovation Act of 2009), and the accompanying FDA regulations, may expose trade secrets of both originators and biosimilar applicants.

Manufacturing processes for biologics include many aspects that could be kept as trade secrets, including precise cell growth conditions, analytical processes, purification process and even characteristics of the cells that produce the drug.

Read the full story here.

Source: FierceBiotech

.

Related Videos
James Chambers, PhD
Screenshot of Adam Colborn, JD during an interview
Kirollos Hanna, PharmD
dr ian neeland
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
A panel of 4 experts on biosimilars
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.